NanoEcho AB participates in the international ultrasound conference, the IEEE International Ultrasonics Symposium (IUS), together with one of the company’s key suppliers, us4us Ltd. Attendance at the conference is a strategic step toward establishing NanoEcho’s presence in the global ultrasound market.
NanoEcho AB has signed a new letter of intent with us4us Ltd. regarding continued collaboration on the product development that was initiated with a letter of intent in July 2022. The collaboration is focused on the development of the next-generation ultrasound scanner module.
NanoEcho has been awarded a grant from the SME (Small and Medium Enterprises) -fund within the European Union Intellectual Property Office to cover initial fees related to a new patent application and trademark protection. These grants are provided to support the management of intellectual property assets for European SMEs.
As part of the process of getting market approval for selling and marketing medical technology equipment, NanoEcho has today taken the first step towards certification by having BSI (British Standard Institute) go through the company’s processes. The aim is to evaluate how well the company complies with the current ISO standard, ISO-13485 Management system for medical technology, and identify any weaknesses in the company’s quality management system.
Vinnova has awarded NanoEcho a grant of SEK 200,000 to develop a pricing strategy for NanoEcho’s diagnostic system. This support was obtained through the Medtech4Health call 2023, which aims to strengthen the competence in small medtech companies.
The basic patent for NanoEcho’s method, previously granted in Japan, Europe, and South Korea, has now been approved also in Canada. The basic patent protects the performance of a hand-held probe with the unique combination of placing an ultrasound transducer together with one or more magnets on the same device. The same patent is under examination in the United States, where the process proceeds according to plan.
NanoEcho strengthens the organization by hiring Ulrika Axelsson as responsible for the company’s clinical operations. Ulrika will be part of the company’s executive management team and will, among other things, be responsible for planning and carrying out the company’s clinical studies, with the goal of getting market approval for NanoEcho’s system for rectal cancer diagnostics.
NanoEcho’s system – intended to meet market requirements – is now being used in an ongoing clinical development study
NanoEcho is developing a system with the aim to offer the healthcare a more precise, simple, and cost-effective rectal cancer diagnosis. The prototype system used in the ongoing investigator-led clinical development studies has now been replaced with a system intended to meet market requirements. The first examination on surgically removed rectal cancer tissue with this system has now been performed.
NanoEcho has now successfully completed the detailed product development phase. The work has resulted in a system that has been developed to meet both the authorities’ and customers’ requirements. This system consists of parts manufactured by the company’s selected partners and key suppliers, Vermon and us4us. The system is now on site at the company’s premises in Lund, ready for integration and evaluation.
An investigator-led clinical development study has started at Skåne University Hospital in Malmö. In this context, the first examination of resected rectal cancer tissue has been performed with the NanoEcho diagnostic system.